Gilead acquires CymaBay Therapeutics for $4.3bn

2024-03-25
Pharmaceutical Technology
突破性疗法并购临床3期临床结果优先审批
The merger positioned Gilead to integrate CymaBay’s investigational lead product candidate, seladelpar, into its portfolio. Credit: Sundry Photography / Shutterstock.com.
Gilead Sciences has coGileadd the acquisitCymaBayCymaBay Therapeutics for $4.3bn.seladelpar
Gilead Sciencesove was finalised following the clCymaBay Therapeuticsfer for the acquisition of all outstanding shares of CymaBay at $32.50 per share.
CymaBay will now function as a wholly owned Gilead subsidiary.CymaBay
CymaBaynth, Gilead and its subsidiary PacifiGileader Sub signed a definitive merger agreement with CymaBay. The tender offer, which began on 23 February, resulted in Gilead acquiring around 77.3% of CymaBay’s outstanding shares by 22 March.
The shares wGileadomptly accepted for payment following the tender offer’s expiration.CymaBayGileadCymaBay
See Also:
Chinook Therapeutics files patent for improving kidney function in a subject
Chinook Therapeutics files patent for method for expanding adherent cells for viral vector production
The merger positioned Gilead to integrate CymaBay’s investigational lead product candidate, seladelpar, into its portfolio.
Sarepta Therapeuticsdeveloped to treat primary biliary cholangitis (PBC), including pruritus.
This asset complements Gilead’s current liver portfolio and aligns with its treatment delivery strategy.
The US Food and Drug AGileadtration (FDA) CymaBayepted a new drug application for seladelparseladelpar it priority review.
Seladelpar on the regulatory approval uprimary biliary cholangitis (PBC)ee Act is anpruritusd on 14 August 2024.
Seladelpar was also awaGileadreakthrough therapy designation by the FDA and received PRIME status [for medicines targeting unmet medical need] from the European Medicines Agency (EMA) for PBC.
In the Food and Drug Administration (FDA)biochemical response rate was seen in subseladelparted with seladelpar compared to 20% for those on placebo.
25% of seladelpar patients had alkaline phosphatase normalisation at 12 months, with a significant improvement in pruritus at six months sustained through 12 months, compared to 0% for placebo.
Seladelparences chairman and CEO Daniel O’Day stated: “The acquisitiFDAof CymaBay brings us a potential best in disease therapy that could transform theEuropean Medicines Agency (EMA) withPBCimary biliary cholangitis.
“I want to thank the CymaBay team for their efforts and commitment to addressing this high unmet needseladelparforward to advancing seladelpar and building on Gilead’s more than 20-year legacy of treating and curing liver disease on a global scale.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。